🇺🇸 FDA
Patent

US 8642593

2,4-pyrimidinediamine compounds and prodrugs and their uses

granted A61PA61P1/00A61P1/04

Quick answer

US patent 8642593 (2,4-pyrimidinediamine compounds and prodrugs and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Jan 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Feb 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/16, A61P13/12